Cervical Cancer Clinical Trial
Official title:
A Double-Blind, Controlled, Randomized, Phase III Study of the Efficacy of an HPV16/18 VLP Vaccine in the Prevention of Advanced Cervical Intraepithelial Neoplasia (CIN2, CIN3, Adenocarcinoma In Situ [AIS] and Invasive Cervical Cancer) Associated With HPV 16 or HPV 18 Cervical Infection in Healthy Young Adult Women in Costa Rica.
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer form forming, growing,
or coming back. Vaccines may help the body build an effective immune response against human
papillomavirus and may be effective in preventing cervical intraepithelial neoplasia or
cervical cancer. It is not yet known whether human papillomavirus vaccine is more effective
than hepatitis A vaccine in preventing cervical intraepithelial neoplasia or cervical cancer.
PURPOSE: This randomized phase III trial is studying human papillomavirus vaccine to see how
well it works compared to hepatitis A vaccine in preventing cervical intraepithelial
neoplasia or cervical cancer in younger healthy participants.
OBJECTIVES:
Primary
•Demonstrate the efficacy of the candidate vaccine, human papillomavirus 16/18 (HPV 16/18) L1
virus-like particle (VLP)/AS04 vaccine compared with control in preventing grade 2 or 3
cervical intraepithelial neoplasia, adenocarcinoma in situ of the cervix, or invasive
cervical cancer (CIN2+) associated with HPV 16 or HPV 18 cervical infection in younger
healthy participants who are negative for HPV DNA by polymerase chain reaction (PCR) for the
corresponding HPV type at months 0 and 6.
Secondary
- Determine the duration of protection against HPV 16 or HPV 18 cervical infection in
participants treated with the HPV 16/18 L1 VLP/AS04 vaccine.
- Determine the safety of this vaccine in these participants, regardless of their initial
HPV 16/18 DNA status.
- Evaluate the efficacy of the candidate vaccine, HPV 16/18 L1 VLP/AS04 vaccine compared
with control in preventing CIN2+ associated with any oncogenic HPV type cervical
infection in participants who are negative for HPV DNA by PCR for the corresponding HPV
type at months 0 and 6.
- Compare the efficacy of the candidate vaccine with control in preventing CIN2+
associated with HPV 16 or HPV 18 cervical infection, detected within the lesional
component of the cervical tissue specimen by PCR, in participants who are negative for
HPV DNA by PCR for the corresponding HPV type at months 0 and 6 and by enzyme-linked
immunosorbent assay (ELISA) at month 0.
- Compare the efficacy of the candidate vaccine with control in preventing persistent HPV
16 or HPV 18 cervical infection in these participants.
- Determine the immunogenicity of HPV 16/18 L1 VLP/AS04 vaccine by ELISA and V5/J4
monoclonal antibody inhibition enzyme immunoassay in the first 600 participants
randomized to receive HPV 16/18 L1 VLP/AS04 vaccine.
OUTLINE: This is a randomized, controlled, double-blind, parallel-group study. Participants
are randomized to 1 of 2 treatment arms.
- Arm I: Participants receive human papillomavirus 16/18 L1 virus-like particle/AS04
vaccine intramuscularly (IM) once in months 0, 1, and 6.
- Arm II: Participants receive hepatitis A vaccine (Havrix®) IM once in months 0, 1, and
6.
After completion of study treatment, participants are followed at 6 months and then at least
annually for 3 years.
PROJECTED ACCRUAL: Approximately 7,500 participants will be accrued for this study.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06223308 -
A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Terminated |
NCT03367871 -
Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04537156 -
Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
|
Phase 3 | |
| Recruiting |
NCT03668639 -
Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
| Withdrawn |
NCT04806945 -
A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT04185389 -
Long-Term Follow-Up of HPV FOCAL Participants
|
||
| Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
| Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
| Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT05120167 -
Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy
|
N/A | |
| Recruiting |
NCT05483491 -
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
| Completed |
NCT05862844 -
Promise Women Project
|
N/A | |
| Recruiting |
NCT04934982 -
Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2)
|
N/A | |
| Recruiting |
NCT03876860 -
An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis
|
N/A | |
| Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT00543543 -
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
|
Phase 3 | |
| Terminated |
NCT04864782 -
QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04226313 -
Self-sampling for Non-attenders to Cervical Cancer Screening
|
N/A |